Novavax, Inc.

NASDAQ:NVAX

Biotechnology

Healthcare
$7.96 -1.84%

-$0.18 today

Market cap
$1.31B
Beta
2.41
P/E (TTM)
-17.3
EPS (TTM)
-$0.54
52W Low $6.13High $11.97

Volume 4.24M

Average 4.58M

NVAX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Novavax, Inc.NASDAQ: NVAX

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin declines year over year

Q1 FY2026 selling, general & admin of $28.78M fell 40.2% year over year, ahead of the -57.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 6.8% from the prior quarter. Over 3 fiscal years it compounded at -32.5% a year.

Context

  • Selling, general & admin amounted to 13.4% of revenue in FY2025, down 36.0 pp from a year earlier.
  • Selling, general & admin increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 5 analysts of $310.98M (+106.8%) for the fiscal year ending Dec 2026, a step up from the -55.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$28.78M+6.8% QoQ
Last fiscal yearDec 2025
$150.35M-55.4% YoY
LTMMar 2026
$127.98M-57.1% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-40.2%-15.0%+25.2 pp
1 year-55.4%+106.8%+162.3 pp
3-year CAGR-32.5%-2.9%+29.6 pp
5-year CAGR+14.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
150.35M USD
Year-over-year change
-55.4%
4-year CAGR
-15.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How NVAX compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -57.1% is the lowest of 8, against a peer median of -7.7%.
  • Selling, general & admin amounts to 21.5% of revenue for NVAX, versus a peer median of 38.8%.
NVAX Competitors
Selling, General & Admin for NVAX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$16.46B USD+48531.9%-28.7%—
MRNAModerna, Inc.LTM Sep 2026$979M USD-7.7%-3.5%38.8%
BNTXBioNTech SELTM Jun 2026€788.8M EUR+45.9%+8.9%29.8%
EBSEmergent BioSolutions Inc.LTM Mar 2026$180.5M USD-32.3%-18.1%26.7%
PCVXVaxcyte, Inc.LTM Jun 2026$132.67M USD+14.1%+48.1%—
NVAXNovavax, Inc.LTM Mar 2026$127.98M USD-57.1%-32.5%21.5%
VALNValneva SELTM Mar 2026€70.46M EUR-23.0%+9.1%45.1%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$43.57M USD-11.6%+0.0%96.1%
Peer median (excluding NVAX) —-7.7%+0.0%38.8%

Competitors are the stored peer set for NVAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue197.58M1.6B556.38M682.16M1.12B
Cost of Revenue0902.64M343.77M202.74M71.14M
Gross Profit197.58M696.31M212.61M479.42M1.05B
Gross Margin100.0%43.5%38.2%70.3%93.7%
Research & Development2.53B1.24B737.5M391.17M336.82M
Selling, General & Admin298.36M488.69M468.95M337.19M150.35M
Operating Expenses1.88B1.34B779.13M728.35M489.07M
Depreciation & Amortization12.66M29.05M41.23M48.5M27.61M
EBITDA(1.68B)(604.71M)(487.39M)(108.04M)492.33M
EBITDA Margin-850.7%-37.8%-87.6%-15.8%43.8%
Operating Income(1.69B)(644.74M)(566.51M)(248.93M)563.27M
Operating Margin-853.6%-40.3%-101.8%-36.5%50.1%
Interest Income00000
Interest Expense21.13M19.88M14.42M20.08M22.55M
Other Income / Expenses(27.96M)(8.91M)23.48M72.32M(121.1M)
Income Before Tax(1.71B)(653.65M)(543.03M)(176.62M)442.17M
Pre-Tax Margin-867.8%-40.9%-97.6%-25.9%39.4%
Income Tax Expense29.22M4.29M2.03M10.88M1.87M
Net Income(1.74B)(657.94M)(545.06M)(187.5M)440.3M
Net Margin-882.5%-41.1%-98.0%-27.5%39.2%
EPS (Basic)(23.44)(8.42)(5.41)(1.23)2.72
EPS (Diluted)(23.44)(8.42)(5.41)(1.23)2.54
Weighted Avg Shares74.4M78.18M100.77M152.19M161.99M
Weighted Avg Shares (Diluted)74.4M78.18M100.77M152.19M173.1M

Novavax, Inc.

NASDAQ:NVAX

Intrinsic Alpha fair value

Locked

Current Price

$7.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.